8802 Federal Register / Vol. 74, No. 37 / Thursday, February 26, 2009 / Notices 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

(Virtual Meeting). 

Contact Person: Bonnie L. Burgess-Beusse, 

PhD, Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2182, 

MSC 7818, Bethesda, MD 20892, 301–435– 

1783, beusseb@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel Diversity 

Fellowships: Division of Translational and 

Clinical Sciences. 

Date: March 24–25, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health. 6701 

Rockledge Drive, Bethesda, MD 20892. 

(Virtual Meeting). 

Contact Person: John Firrell, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5213, 

MSC 7854, Bethesda, MD 20892, 301–435– 

2598, firrellj@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, 

Technologies in Cell Biology. 

Date: March 24–25, 2009. 

Time: 9 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

(Virtual Meeting). 

Contact Person: Noni Byrnes, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5130, 

MSC 7840, Bethesda, MD 20892, (301) 435– 

1023, byrnesn@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: February 18, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–3944 Filed 2–25–09; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request 

In compliance with Section 

3506(c)(2)(A) of the Paperwork 

Reduction Act of 1995 concerning 

opportunity for public comment on 

proposed collections of information, the 

Substance Abuse and Mental Health 

Services Administration (SAMHSA) 

will publish periodic summaries of 

proposed projects. To request more 

information on the proposed projects or 

to obtain a copy of the information 

collection plans, call the SAMHSA 

Reports Clearance Officer on (240) 276– 

1243. 

Comments are invited on: (a) Whether 

the proposed collections of information 

are necessary for the proper 

performance of the functions of the 

agency, including whether the 

information shall have practical utility; 

(b) the accuracy of the agency’s estimate 

of the burden of the proposed collection 

of information; (c) ways to enhance the 

quality, utility, and clarity of the 

information to be collected; and (d) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques or 

other forms of information technology. 

Proposed Project: Rapid HIV Testing 

Clinical Information Form for the 

Minority AIDS Initiative (MAI) for 

Ethnic and Racial Minorities at Risk for 

Substance Use and HIV/AID—In Use 

Without OMB Approval 

The Substance Abuse and Mental 

Health Services Administration’s 

(SAMHSA) Center for Substance Abuse 

Treatment (CSAT), is requesting an 

OMB review and approval of the 

Minority AIDS Initiative (MAI) Rapid 

HIV Testing Clinical Information Form 

that will be utilized for ethnic and racial 

minority groups at risk for substance use 

and HIV/AIDS that are served by 

CSAT’s TCE–HIV grantees. The MAI 

HIV Rapid Testing Clinical Information 

Form would allow SAMHSA/CSAT to 

collect essential clinical information 

that will be used for quality assurance, 

quality performance, and product 

monitoring on approximately 30,000 

rapid HIV test kits to be provided to 

ethnic and racial minority communities 

at no cost to the recipient provider 

organizations. The MAI Rapid HIV 

Testing Clinical Information Form 

would support quality of care, provide 

adequate clinical and product 

monitoring, and provide appropriate 

safeguards against fraud, waste and 

abuse of Federal funds. SAMHSA’s 

approach would avoid unnecessary 

delay in informing any person 

potentially adversely affected by a test 

kit recall or public health advisory. This 

program is authorized under Section 

509 of the Public Health Service (PHS) 

Act [42 U.S.C. 290bb–2]. 

The goals of SAMHSA’s MAI 

initiative are to: (1) Increase the access 

by racial and ethnic minority 

communities to HIV testing, prevention, 

care, and treatment services; (2) 

implement strategies and activities 

specifically targeted to the highest risk 

and hardest-to-serve populations; (3) 

reduce the stigma associated with HIV/ 

AIDS screening through outreach and 

education, and (4) establish 

collaborations or opportunities for 

programs and/or activities to be 

integrated. 

The target populations for the 

initiative are African Americans, 

Hispanic/Latinos, and other racial and 

ethnic minorities that are 

disproportionately impacted by the twin 

epidemics of HIV/AIDS and substance 

abuse. Since 1981 approximately 1.7 

million people are estimated to have 

been infected with HIV in the U.S., and 

more than 1.1 million are estimated to 

be living with HIV/AIDS today. Racial 

and ethnic minorities have been 

disproportionately affected by HIV/ 

AIDS, and represent the majority of new 

AIDS cases (70%), new HIV infections 

(54%), prevalent HIV/AIDS cases (65%), 

and AIDS deaths (72%) (CDC, 2006). 

African Americans have been especially 

affected by HIV/AIDS. More than half of 

all new HIV infections and half of new 

AIDS diagnoses occur in African 

Americans despite their accounting for 

approximately 12% of the U.S. 

population. A similar impact exists 

among Latinos, who represent 14% of 

the U.S. population but account for 20% 

of estimated AIDS diagnoses. Together, 

Asian/Pacific Islanders and American 

Indian/Alaska Natives represent 1%– 

2% of new AIDS diagnoses. 

The spread of HIV disease in the 

United States has been partly fueled by 

the use of illicit drugs. Injection drug 

use (IDU) is directly related to HIV 

transmission through the sharing of 

drug equipment. According to CDC’s 

latest report on 2006 rates, IDUs 

accounted for 12 percent of estimated 

new HIV infections. CDC’s historical 

trend analysis indicates that new 

infections have declined dramatically in 

this population over time and confirm 

the substantial evidence to date of 

success in reducing HIV infections 

among IDUs. Despite these declines, 

rates of HIV and AIDS continue to rise 

among certain groups including men 

who have sex with men, high risk 

heterosexual women and ethnic and 

racial minority groups due to non-IDU 

drugs and alcohol that interfere with 

judgment about sexual and other types 

of behaviors. 

The estimated hour burden is 

presented in the following table: 

Federal Register / Vol. 74, No. 37 / Thursday, February 26, 2009 / Notices 8803 

Number of respondents Responses/ 

respondent Burden hours Total burden hours 

30,000 .......................................................................................................................................... 1 .167 5,010 

Send comments to Summer King, 

SAMHSA Reports Clearance Officer, 

Room 7–1044, One Choke Cherry Road, 

Rockville, MD 20857 and e-mail her a 

copy at summer.king@samhsa.hhs.gov. 

Written comments should be received 

within 60 days of this notice. 

Dated: February 20, 2009. 

Elaine Parry, 

Director, Office of Program Services. 

[FR Doc. E9–4088 Filed 2–25–09; 8:45 am] 

BILLING CODE 4162–20–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

Periodically, the Substance Abuse and 

Mental Health Services Administration 

(SAMHSA) will publish a summary of 

information collection requests under 

OMB review, in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

Chapter 35). To request a copy of these 

documents, call the SAMHSA Reports 

Clearance Officer on (240) 276–1243. 

Project: Notification of Intent To Use 

Schedule III, IV, or V Opioid Drugs for 

the Maintenance and Detoxification 

Treatment of Opiate Addiction Under 

21 U.S.C. 823(g)(2) (OMB No. 0930– 

0234)—Revision 

The Drug Addiction Treatment Act of 

2000 (‘‘DATA,’’ Pub. L. 106–310) 

amended the Controlled Substances Act 

(21 U.S.C. 823(g)(2)) to permit 

practitioners (physicians) to seek and 

obtain waivers to prescribe certain 

approved narcotic treatment drugs for 

the treatment of opiate addiction. The 

legislation sets eligibility requirements 

and certification requirements as well as 

an interagency notification review 

process for physicians who seek 

waivers. The legislation was amended 

in 2005 to eliminate the patient limit for 

physicians in group practices, and in 

2006, to permit certain physicians to 

treat up to 100 patients. 

To implement these provisions, 

SAMHSA developed a notification form 

(SMA–167) that facilitates the 

submission and review of notifications. 

The form provides the information 

necessary to determine whether 

practitioners (i.e., independent 

physicians) meet the qualifications for 

waivers set forth under the new law. 

Use of this form will enable physicians 

to know they have provided all 

information needed to determine 

whether practitioners are eligible for a 

waiver. 

However, there is no prohibition on 

use of other means to provide requisite 

information. The Secretary will convey 

notification information and 

determinations to the Drug Enforcement 

Administration (DEA), which will 

assign an identification number to 

qualifying practitioners; this number 

will be included in the practitioner’s 

registration under 21 U.S.C. 823(f). 

Practitioners may use the form for 

three types of notification: (a) New, (b) 

immediate, and (c) to notify of their 

intent to treat up to 100 patients. Under 

‘‘new’’ notifications, practitioners may 

make their initial waiver requests to 

SAMHSA. ‘‘Immediate’’ notifications 

inform SAMHSA and the Attorney 

General of a practitioner’s intent to 

prescribe immediately to facilitate the 

treatment of an individual (one) patient 

under 21 U.S.C. 823(g)(2)(E)(ii). Finally, 

the form may be used by physicians 

with waivers to certify their need and 

intent to treat up to 100 patients. 

The form collects data on the 

following items: Practitioner name; 

State medical license number and DEA 

registration number; address of primary 

location, telephone and fax numbers; email address; purpose of notification 

new, immediate, or renewal; 

certification of qualifying criteria for 

treatment and management of opiate 

dependent patients; certification of 

capacity to refer patients for appropriate 

counseling and other appropriate 

ancillary services; certification of 

maximum patient load, certification to 

use only those drug products that meet 

the criteria in the law. The form also 

notifies practitioners of Privacy Act 

considerations, and permits 

practitioners to expressly consent to 

disclose limited information to the 

SAMHSA Buprenorphine Physician 

Locator. 

Since July 2002, SAMHSA has 

received over 17,000 notifications and 

has certified almost 16,000 physicians. 

Eighty-one percent of the notifications 

were submitted by mail or by facsimile, 

with approximately twenty percent 

submitted through the Web based online 

system. Approximately 60 percent of the 

certified physicians have consented to 

disclosure on the SAMHSA 

Buprenorphine Physician Locator. 

Respondents may submit the form 

electronically, through a dedicated Web 

page that SAMHSA will establish for the 

purpose, as well as via U.S. mail. 

The following table summarizes the 

estimated annual burden for the use of 

this form. 

Purpose of submission Number of 

respondents 

Responses 

per 

respondent 

Burden per 

response 

(hr.) 

Total burden 

(hrs) 

Initial Application for Waiver ............................................................................ 1,500 1 .083 125 

Notification to Prescribe Immediately .............................................................. 50 1 .083 4 

Notice to Treat up to 100 patients ................................................................... 500 1 .040 20 

Total ................................................................................................... 2,050 ........................ ........................ 149 

Written comments and 

recommendations concerning the 

proposed information collection should 

be sent by March 30, 2009 to: SAMHSA 

Desk Officer, Human Resources and 

Housing Branch, Office of Management 

and Budget, New Executive Office 

Building, Room 10235, Washington, DC 

20503; due to potential delays in OMB’s 

receipt and processing of mail sent 

through the U.S. Postal Service, 

respondents are encouraged to submit 

comments by fax to: 202–395–6974.